[go: up one dir, main page]

MX2018009008A - Virus atenuados de bronquitis infecciosa. - Google Patents

Virus atenuados de bronquitis infecciosa.

Info

Publication number
MX2018009008A
MX2018009008A MX2018009008A MX2018009008A MX2018009008A MX 2018009008 A MX2018009008 A MX 2018009008A MX 2018009008 A MX2018009008 A MX 2018009008A MX 2018009008 A MX2018009008 A MX 2018009008A MX 2018009008 A MX2018009008 A MX 2018009008A
Authority
MX
Mexico
Prior art keywords
infectious bronchitis
bronchitis virus
attenuated infectious
attenuated
coronavirus
Prior art date
Application number
MX2018009008A
Other languages
English (en)
Inventor
Bickerton Erica
Keep Sarah
Britton Paul
Original Assignee
The Pirbright Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Pirbright Inst filed Critical The Pirbright Inst
Publication of MX2018009008A publication Critical patent/MX2018009008A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20061—Methods of inactivation or attenuation
    • C12N2770/20062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona un coronavirus atenuado vivo que comprende una mutación en la proteína estructural nsp-3 y/o eliminación de proteínas accesorias 3a y 3b. El coronavirus se puede usar como una vacuna para tratar y/o prevenir una enfermedad, tal como bronquitis infecciosa, en un paciente.
MX2018009008A 2016-01-27 2017-01-26 Virus atenuados de bronquitis infecciosa. MX2018009008A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1601498.7A GB201601498D0 (en) 2016-01-27 2016-01-27 Coronavirus
PCT/GB2017/050192 WO2017129975A1 (en) 2016-01-27 2017-01-26 Attenuated infectious bronchitis virus

Publications (1)

Publication Number Publication Date
MX2018009008A true MX2018009008A (es) 2018-11-19

Family

ID=55535017

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009008A MX2018009008A (es) 2016-01-27 2017-01-26 Virus atenuados de bronquitis infecciosa.

Country Status (17)

Country Link
US (1) US11202825B2 (es)
EP (1) EP3408381B1 (es)
JP (1) JP2019503693A (es)
KR (1) KR20180104088A (es)
CN (1) CN108884447B (es)
AU (1) AU2017211507B2 (es)
BR (1) BR112018015453A2 (es)
CA (1) CA3012024A1 (es)
CL (1) CL2018001946A1 (es)
GB (1) GB201601498D0 (es)
IL (1) IL259655A (es)
MX (1) MX2018009008A (es)
PE (1) PE20190121A1 (es)
PH (1) PH12018501154A1 (es)
RU (1) RU2018130683A (es)
WO (1) WO2017129975A1 (es)
ZA (1) ZA201803700B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110592031B (zh) * 2019-09-25 2023-03-14 华南农业大学 一株S蛋白融合HiBiT的传染性支气管炎重组病毒及制备方法与应用
CN111437384A (zh) * 2020-04-07 2020-07-24 四川骋誉生物制品有限公司 用于预防covid-19的蝙蝠源性冠状病毒疫苗
BR102020019867A2 (pt) * 2020-09-28 2022-04-12 Fundacao Univ Estadual Do Ceara Funece Uso da vacina de coronavírus aviário (ibv) como modelo de imunização em mamíferos contra sars-cov 2
JP2024004496A (ja) * 2020-10-14 2024-01-17 一般財団法人阪大微生物病研究会 ノックアウトコロナウイルス
CN113308440B (zh) * 2021-05-26 2023-04-28 武汉大学 一种n7-甲基转移酶缺陷型冠状病毒减毒疫苗株及其制备方法与应用
CN114807061A (zh) * 2021-12-22 2022-07-29 华南农业大学 鸡传染性支气管炎标记疫苗毒株及其制备方法、疫苗

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037650A (en) 1988-03-08 1991-08-06 Akzo N.V. Live combination vaccine
UA73718C2 (en) 1998-05-01 2005-09-15 Schering Plough Ltd Therapeutic vector expressing foreign dna, coding cat's cd80, cat's cd86, cat's cd28 or cat's ctla-4 and use thereof
ATE473274T1 (de) 2001-05-17 2010-07-15 Univ Utrecht Coronavirus-ähnliche partikel enthaltende funktionell deletierte genome
PL1610817T3 (pl) 2003-03-03 2010-05-31 Intervet Int Bv Wirus zakaźnego zapalenia oskrzeli ze zmienionym genem wypustek
RU2253870C1 (ru) 2004-04-26 2005-06-10 Общество с ограниченной ответственностью Научно-производственное объединение "Диагностические системы" РЕКОМБИНАНТНЫЕ БЕЛКИ, СОДЕРЖАЩИЕ ДИАГНОСТИЧЕСКИ ЗНАЧИМЫЕ АНТИГЕННЫЕ ЭПИТОПЫ БЕЛКОВ КОРОНАВИРУСА (SARS-CoV), СВЯЗАННОГО С ТЯЖЕЛЫМ ОСТРЫМ РЕСПИРАТОРНЫМ СИНДРОМОМ, И ПОСЛЕДОВАТЕЛЬНОСТИ СИНТЕТИЧЕСКИХ ГЕНОВ, КОДИРУЮЩИХ ДИАГНОСТИЧЕСКИ ЗНАЧИМЫЕ АНТИГЕННЫЕ ДЕТЕРМИНАНТЫ БЕЛКОВ КОРОНАВИРУСА (SARS-CoV), СВЯЗАННОГО С ТЯЖЕЛЫМ ОСТРЫМ РЕСПИРАТОРНЫМ СИНДРОМОМ
KR100902510B1 (ko) * 2007-08-27 2009-06-15 삼성전자주식회사 한 개의 스위칭 소자와 한 개의 저항체를 포함하는비휘발성 메모리 장치
GB0911794D0 (en) 2009-07-07 2009-08-19 Animal Health Inst Chimaeric protein

Also Published As

Publication number Publication date
EP3408381A1 (en) 2018-12-05
KR20180104088A (ko) 2018-09-19
JP2019503693A (ja) 2019-02-14
RU2018130683A (ru) 2020-02-27
EP3408381B1 (en) 2021-06-23
AU2017211507A1 (en) 2018-06-28
US20190022214A1 (en) 2019-01-24
RU2018130683A3 (es) 2020-04-21
ZA201803700B (en) 2022-12-21
GB201601498D0 (en) 2016-03-09
CL2018001946A1 (es) 2019-02-15
PE20190121A1 (es) 2019-01-17
CN108884447A (zh) 2018-11-23
WO2017129975A1 (en) 2017-08-03
PH12018501154A1 (en) 2019-01-28
AU2017211507B2 (en) 2022-09-29
BR112018015453A2 (pt) 2018-12-18
CN108884447B (zh) 2022-07-26
US11202825B2 (en) 2021-12-21
IL259655A (en) 2018-07-31
CA3012024A1 (en) 2017-08-03

Similar Documents

Publication Publication Date Title
PH12018501154A1 (en) Attenuated infectious bronchitis virus
MX2016016722A (es) Coronavirus.
PH12020500080A1 (en) Senecavirus a immunogenic compositions and methods thereof
EP4477662A3 (en) Nucleic acid molecules and uses thereof
EA201890527A1 (ru) Терапевтические вакцины против hpv18
EA030115B9 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
EA201991862A1 (ru) Композиции и способы, предназначенные для лечения гемоглобинопатий
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
JO3564B1 (ar) ببتيدات وتركيبات لعلاج ضرر المفاصل
EA201790294A1 (ru) Средства на основе флагеллина и применения, включающие эффективную вакцинацию
ZA202403393B (en) Synthetic chimeric poxviruses
MX2016013819A (es) Vacuna profilactica contra el sindrome de caida del huevo (eds).
PH12017500450A1 (en) Flavivirus virus like particle
MX379510B (es) Coronavirus bovino atenuado y vacunas relacionadas.
MX2018006416A (es) Metodos para el tratamiento, prevencion y diagnostico de infeccion por el virus de la diarrea epidemica porcina.
PH12016502002A1 (en) Novel bacteriophage and composition comprising same
MX2018005462A (es) Composiciones inmunogénicas de rsv quimérico y métodos de uso.
UA122339C2 (uk) Вірус качиного ентериту та його застосування
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
PH12016502001A1 (en) Novel bacteriophage and composition comprising same
PH12017500088A1 (en) Antagonists of neurokinin b in fish reproduction
WO2018035199A8 (en) Sea lice vaccine
EA201891555A1 (ru) Вирус вакцины от репродуктивно-респираторного синдрома свиней
PH12016502000B1 (en) Novel bacteriophage and composition comprising same
NZ728041A (en) Substances and methods for the use in prevention and/or treatment in huntington’s disease